title: Bimatoprost 0.01 % for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical setting.
abstract: OBJECTIVE
  To evaluate the occurrence of hyperemia with, and efficacy of, bimatoprost 0.01 % for patients in Korea previously treated for open-angle glaucoma (OAG; including normal tension glaucoma) or ocular hypertension (OHT).
  
  
  METHODS
  In this multicenter, observational study (Asia Pacific Patterns from Early Access of Lumigan 0.01 % in Korea; APPEAL Korea), patients with unachieved target intraocular pressure (IOP) despite previous treatment received bimatoprost 0.01 % daily for 12 weeks. The primary endpoint was incidence of hyperemia and its severity, graded using the standard 5-point photographic scale and grouped as "none to mild" and "moderate to severe". Hyperemia shifts were reported. IOP and adverse events (AEs) were recorded.
  
  
  RESULTS
  Of 800 patients (intent-to-treat/safety population), 248 were switched from previous treatment to bimatoprost 0.01 % monotherapy. Hyperemia shifts from baseline at weeks 6 and 12 were unchanged (84.8, 89.8 %), improved (4.4, 4.8 %), or worsened (10.8, 5.4 %), respectively. The shift was significant at week 6 (P < 0.0001). Hyperemia did not worsen significantly in patients previously receiving a prostaglandin analog or prostamide (PGA/PSD). Baseline mean IOP ± SD was 17.0 ± 5.7 mmHg, decreasing to 14.6 ± 3.8 mmHg (P < 0.0001) after 6 weeks, and to 14.7 ± 3.6 mmHg (P < 0.0001) after 12 weeks. Patients switched from PGA or PSD (excluding bimatoprost 0.03 %) to bimatoprost 0.01 % experienced significant IOP reductions from baseline. Treatment-related ocular AEs were reported by 37 patients, the most common being hyperemia (7.3 %).
  
  
  CONCLUSIONS
  This subanalysis of the APPEAL Korea study supports use of bimatoprost 0.01 % for previously treated patients with OAG (including normal tension glaucoma) or OHT who did not reach target IOP or were intolerant of previous treatment.
authors.affiliation: Department of Ophthalmology, Asan Medical Centre, 388-1 Pungnap-dong, Songpa-Gu, Seoul, Korea. mskook@amc.seoul.kr.
authors.forename: Michael Scott
authors.initials: MS
authors.lastname: Kook
authors.affiliation: Allergan Singapore Pte, Ltd., Mapletree Business City, Singapore, Singapore.
authors.forename: Susan
authors.initials: S
authors.lastname: Simonyi
authors.affiliation: Kim's Eye Hospital, Seoul, Korea.
authors.forename: Yong Ho
authors.initials: YH
authors.lastname: Sohn
authors.affiliation: Department of Ophthalmology, Yonsei University, College of Medicine, Seoul, Korea.
authors.forename: Chan Yun
authors.initials: CY
authors.lastname: Kim
authors.affiliation: Department of Ophthalmology, Seoul National University Hospital, Seoul, Korea.
authors.forename: Ki Ho
authors.initials: KH
authors.lastname: Park
mesh_terms: D000287:Administration, Topical; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D044466:Asian People; D000069580:Bimatoprost / Q000627:therapeutic use*; D003228:Conjunctiva / Q000098:blood supply; D057915:Drug Substitution; D005260:Female; D005902:Glaucoma, Open-Angle / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006940:Hyperemia / Q000503:physiopathology; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D009883:Ophthalmic Solutions; D056910:Republic of Korea; D016037:Single-Blind Method; D014065:Tonometry, Ocular
chemical_list: D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D000069580:Bimatoprost
keywords: Bimatoprost; Glaucoma; Hyperemia; Ocular hypertension; Prostamide